ExpreS2ion Biotech Holding AB (EXPRS2)

Currency in SEK
25.00
-0.85(-3.29%)
Real-time Data·

EXPRS2 Financial Summary

Key Ratios

P/E Ratio-1.27
Price/Book1.13
Debt / Equity3.38%
Return on Equity-66.93%
Dividend Yield0.00%
EBITDA-66.05M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of SEK (except for per share items)

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 0.00

Earnings

Latest Release
May 16, 2025
EPS / Forecast
-4.30 / --
Revenue / Forecast
2.96M / --
EPS Revisions
Last 90 days

FAQ

What were ExpreS2ion Biotech's earnings for the latest quarter?

The ExpreS2ion Biotech EPS (TTM) is -17.02. ExpreS2ion Biotech reported sales of 2.96, net income of -11.44, and EPS of -4.30 for the latest quarter.

What was ExpreS2ion Biotech's net income for the latest quarter?

ExpreS2ion Biotech's net income for the latest quarter was -11.44.

How did ExpreS2ion Biotech's performance compare year-over-year in the latest quarter?

The company's revenue moved from 2.18 in the previous quarter to 2.96 in the latest quarter, and net income moved from -15.26 to -11.44 compared to the previous quarter.

What is ExpreS2ion Biotech's net profit margin on a TTM basis?

ExpreS2ion Biotech's trailing twelve months (TTM) net profit margin is -460.55%.

How does ExpreS2ion Biotech's debt to equity ratio compare to industry standards?

ExpreS2ion Biotech's total debt-to-equity ratio is 3.38%.

What is ExpreS2ion Biotech's return on investment on a TTM basis?

ExpreS2ion Biotech's trailing twelve months (TTM) return on investment (ROI) is -66.93%.

Did ExpreS2ion Biotech gain or lose cash last quarter?

In the latest quarter, ExpreS2ion Biotech's net change in cash was -23.54 million.

What were ExpreS2ion Biotech's total assets and liabilities in the latest quarter?

As of the latest quarter, ExpreS2ion Biotech reported total assets of 80.60 million and total liabilities of 27.67 million.

How has ExpreS2ion Biotech's total revenue grown this year?

ExpreS2ion Biotech's total revenue was 2.18 in the previous quarter and 2.96 in the latest quarter.

What is ExpreS2ion Biotech's gross margin on a TTM basis?

ExpreS2ion Biotech's trailing twelve months (TTM) gross margin is 43.34%.

What was ExpreS2ion Biotech's revenue per share for the latest quarter?

ExpreS2ion Biotech's revenue per share for the latest quarter was 35.69.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.